Half of Americans Support Weight-Loss Drugs Like Ozempic for Obesity, Poll
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching hundreds of dollars per prescription. The poll found that about half of Americans support Medicare and Medicaid covering weight-loss drugs for those with obesity, while around 20 percent oppose it and 25 percent are neutral.
A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.
Other analysts are more cautious, however, predicting peaks sales of $1 billion or lower and pointing to lacklustre take-up of other new obesity drugs such as Eisai and Arena's Belviq ...
an oncologist at Memorial Sloan Kettering Cancer Center in New York City. Iyengar researches the relationship between obesity and cancer. “I foresee that this class of drugs will revolutionize ...
Beyond obesity, potential indications for these drugs include sleep apnea, addiction, Alzheimer’s disease, and metabolic dysfunction-associated steatohepatitis (MASH). New medications for ...
Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new ... obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2 programme for the drug ...
Eli Lilly and Novo Nordisk have been competing in the obesity ... for both drugs. Novo Nordisk’s Wegovy made a significant impact on the obesity market when it launched in 2021.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback